Stocks
SpringWorks Therapeutics, Inc.SWTX
NASDAQHealthcareBiotechnology$46.99+0.02%
Price as of · delayed, not real-time
Focused on developing targeted oncology therapies, this biopharmaceutical company specializes in rare cancers and precision medicine. Its lead drug candidate, nirogacestat, is in late-stage trials for desmoid tumors, drawing investor attention to its potential in underserved markets.
Market Cap: $3.5B52W Range: $28.21-$62.00
Congressional Interest in SpringWorks Therapeutics, Inc. (SWTX)
3 members of Congress have disclosed 8 trades in SpringWorks Therapeutics, Inc. (SWTX), a Healthcare company. The buy/sell breakdown shows 5 purchases versus 3 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
8
Unique Politicians
3
Buys
5
Sells
3
Who in Congress Is Trading SWTX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-07-02 | Josh Gottheimer | sell | $1K-$15K |
| 2025-07-01 | Gilbert Cisneros | sell | $15K-$50K |
| 2025-01-29 | Gilbert Cisneros | buy | $1K-$15K |
| 2024-09-05 | Josh Gottheimer | buy | $1K-$15K |
| 2024-07-19 | Josh Gottheimer | buy | $1K-$15K |
| 2024-06-18 | Josh Gottheimer | sell | $1K-$15K |
| 2024-05-09 | Josh Gottheimer | buy | $1K-$15K |
| 2022-12-12 | Christopher L. Jacobs | buy | $1K-$15K |